Search

Your search keyword '"Gonciarz, Maciej"' showing total 131 results

Search Constraints

Start Over You searched for: Author "Gonciarz, Maciej" Remove constraint Author: "Gonciarz, Maciej"
131 results on '"Gonciarz, Maciej"'

Search Results

1. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

2. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

3. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

4. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

5. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

6. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

9. Su1779 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) FOR ULCERATIVE COLITIS: 2-YEAR EXTENSION RESULTS OF THE LIBERTY-UC STUDY

10. Su1762 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: 2 YEARS RESULTS OF THE LIBERTY-CD STUDY

12. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

14. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

20. Tu1701 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE THERAPY FOR ULCERATIVE COLIITS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY: RESULTS OF THE LIBERTY-UC STUDY

21. 1028 SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD).

22. Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology

26. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

29. Ferrytyna - udział w gospodarce żelazem i znaczenie diagnostyczne.

31. Possible under-treatment of women in Poland with Crohn’s disease: a subgroup analysis from a prospective multicenter study of the use of anti-TNFs

34. New pharmaceuticals in inflammatory bowel disease

35. Genetic aspects of colorectal carcinogenesis

37. Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology

38. Guidelines for the management of ulcerative colitis. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology

41. Guidelines for the management of antiplatelet and anticoagulant therapy in patients undergoing endoscopic procedures. Recommendations of the Working Group of the Polish Society of Gastroenterology and the Polish Consultant in Gastroenterology

42. Guidelines for the management of Crohn’s disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology

Catalog

Books, media, physical & digital resources